Collaboration Exploits Cellzome's World-Leading Proteomics Technology in
Epigenetics
Cellzome today announced that it has formed a second strategic alliance
with GlaxoSmithKline (GSK). This new collaboration gives GSK exclusive access
to Cellzome's proprietary Episphere(TM) technology in the emerging field of
epigenetics as applied to immunoinflammatory disease. Epigenetic mechanisms
play a key role in controlling immune cell differentiation and inflammatory
gene expression during an excessive inflammatory response.
Under the terms of the agreement, the companies will work together using
Cellzome's Episphere(TM) technology platform, to identify selective
small-molecule drug candidates against targets from four different epigenetic
target classes. The companies will share operational responsibility for the
programs until identification of drug candidates, at which stage GSK will
assume responsibility for any further preclinical and clinical development
and commercialisation.